



ASX ANNOUNCEMENT

21 March 2024

Resignation of CEO

21 March 2024 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that Chief Executive Officer, Peter Koetsier, has given notice of his resignation from the position as CEO, for family reasons. Non-executive Director Ms Jenni Pilcher will assume an Executive Director role at the company while the Board sets its new strategic direction. Peter will work through a handover period and is expected to finish up at the end of the financial year.

Commenting on his decision, Mr Koetsier said: “I want to express my deepest gratitude to the board, employees, and stakeholders of Cann for their support and collaboration during my time as CEO. I am truly grateful for the opportunity to have worked alongside such talented and dedicated individuals.”

Cann Group Chairman, Dr Julian Chick, said, “We are grateful for Peter’s efforts over the past 14 months in scaling up of our business which has led to the production of over 12 tonnes of product per annum, and increased sales. I wish Peter well in his next endeavour.”

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Jackson Paine
Corporate Communications Manager
+61 439 492 955
jackson.paine@canngrouponlimited.com

For all other information please contact:

Steven Notaro
Head of Legal & Regulatory Affairs and
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com

Cann Group Limited

ACN 25 603 949 739, Australia

262-276 Lorimer Street, Port Melbourne 3207, Victoria, Australia

Tel +61 (0) 3 9095 7088 | www.canngrouponlimited.com